Trial · NCT00545779
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Current Daily or Weekly Bisphosphonate Users in Part A Who Answer 'Yes' to Any of the Questions in the Candidate Identification Questionnaire (CIQ) | Ibandronate | 68.1 | percentage of participants | ||
| Percentage of Participants Who Reported Preference for Monthly Ibandronate | Ibandronate | 67.5 | percentage of participants | ||
| Percentage of Participants With Positive Change in Total Composite Satisfaction Score (CSS) at Month 6 in Part B by CIQ Fracture (Fr) Group | Ibandronate | Participants answer Yes with previous Fr (n=115) | 86.1 | percentage of participants | |
| Percentage of Participants With Positive Change in Total Composite Satisfaction Score (CSS) at Month 6 in Part B by CIQ Fracture (Fr) Group | Ibandronate | Participants answer Yes without previous Fr(n=310) | 89.0 | percentage of participants | |
| Percentage of Participants With Positive Change in Total Composite Satisfaction Score (CSS) at Month 6 in Part B by CIQ Fracture (Fr) Group | Ibandronate | Participants answer NO with previous Fr (n=47) | 87.2 | percentage of participants | |
| Percentage of Participants With Positive Change in Total Composite Satisfaction Score (CSS) at Month 6 in Part B by CIQ Fracture (Fr) Group | Ibandronate | Participants answer NO without previous Fr (n=155) | 77.4 | percentage of participants | |
| Percentage of Participants Eligible Current Daily or Weekly Bisphosphonate Users at Screening Who Elect to Enter Part B by CIQ | Ibandronate | Answered Yes to at least 1 question in CIQ | 68.1 | percentage of participants | |
| Percentage of Participants Eligible Current Daily or Weekly Bisphosphonate Users at Screening Who Elect to Enter Part B by CIQ | Ibandronate | Answered NO to every question in CIQ | 31.9 | percentage of participants | |
| Percentage of Participants Who Reported an Improved Satisfaction Score After 6 Months in Part B | Ibandronate | CIQ Question 1 = Yes (n=422) | 88.2 | percentage of participants | |
| Percentage of Participants Who Reported an Improved Satisfaction Score After 6 Months in Part B | Ibandronate | CIQ Question 1 = No (n=205) | 80.0 | percentage of participants | |
| Percentage of Participants Who Reported an Improved Satisfaction Score After 6 Months in Part B | Ibandronate | CIQ Question 2 = Yes (n=115) | 93.0 | percentage of participants | |
| Percentage of Participants Who Reported an Improved Satisfaction Score After 6 Months in Part B | Ibandronate | CIQ Question 2 = No (n=512) | 83.8 | percentage of participants | |
| Percentage of Participants Who Reported an Improved Satisfaction Score After 6 Months in Part B | Ibandronate | CIQ Question 3 = Yes (n=97) | 94.8 | percentage of participants | |
| Percentage of Participants Who Reported an Improved Satisfaction Score After 6 Months in Part B | Ibandronate | CIQ Question 3 = No (n=530) | 83.8 | percentage of participants | |
| Percentage of Participants Who Have Greater Than or Equal to (>=) 80% Compliance With 6 Monthly Doses of Ibandronate in Part B | Ibandronate | 98.6 | percentage of participants | ||
| Percentage of Participants Who Choose a Monthly Reminder to Take Ibandronate in Part B | Ibandronate | 99.4 | percentage of participants | ||
| Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) Domain Scores in Part B | Ibandronate | Baseline: Convenience | 58.4 | Standard Deviation 25.4 | units on a scale |
| Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) Domain Scores in Part B | Ibandronate | Month 6: Convenience | 89.2 | Standard Deviation 11.2 | units on a scale |
| Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) Domain Scores in Part B | Ibandronate | Baseline: Confidence with daily functioning | 62.6 | Standard Deviation 25.6 | units on a scale |
| Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) Domain Scores in Part B | Ibandronate | Month 6: Confidence with daily functioning | 86.6 | Standard Deviation 14.8 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00545779/results